Aytu Biopharma (AYTU) Non-Current Assets (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Non-Current Assets data on file, last reported at $44.4 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 14.17% year-over-year to $44.4 million in Q1 2026; TTM through Mar 2026 was $44.4 million, a 14.17% decrease from a year earlier, with the FY2025 full-year figure at $45.0 million, down 19.94% from the prior year.
• Non-Current Assets for Q1 2026 stood at $44.4 million, down from $45.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for AYTU reached as high as $90.9 million in Q1 2022 and fell as low as $43.9 million in Q3 2025.
• Historically, Non-Current Assets has averaged $60.2 million across 5 years, with a median of $57.7 million in 2024.
• Across the five-year window, Non-Current Assets tumbled 51.57% in 2022 and slipped 10.47% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $70.8 million in 2022, then declined by 15.46% to $59.9 million in 2023, then declined by 11.2% to $53.2 million in 2024, then decreased by 13.94% to $45.8 million in 2025, then declined by 3.05% to $44.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $44.4 million in Q1 2026, $45.8 million in Q4 2025, and $43.9 million in Q3 2025.